DiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance.
DiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.1 million, plus short-term investments of $38.4 million, $43.5 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about DiaMedica Therapeutics
Has DiaMedica Therapeutics raised money recently?
Our latest story on this, dated Aug 12, 2025: "DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of DiaMedica Therapeutics?
DiaMedica Therapeutics Inc. trades under the ticker DMAC on NASDAQ.
Where is DiaMedica Therapeutics listed?
DiaMedica Therapeutics Inc. is listed on NASDAQ.
What is the SEC CIK of DiaMedica Therapeutics?
The SEC Central Index Key (CIK) for DiaMedica Therapeutics Inc. is 1401040. Its filings are on SEC EDGAR.
How many shares does DiaMedica Therapeutics have outstanding?
53,925,697 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is DiaMedica Therapeutics listed under?
Our directory records DiaMedica Therapeutics Inc. under United States.
What does DiaMedica Therapeutics do?
Our directory classifies DiaMedica Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of DiaMedica Therapeutics?
The ISIN recorded for DiaMedica Therapeutics Inc. is CA25253X2077.
Does aibio.space cover DiaMedica Therapeutics?
aibio.space lists DiaMedica Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is DiaMedica Therapeutics incorporated?
SEC records list its state or country of incorporation as Z4.
Is DiaMedica Therapeutics profitable?
DiaMedica Therapeutics Inc. reported a net loss of $32.8 million for the fiscal year ended Dec 31, 2025, and used $29.1 million of cash in operations, per its annual report to the SEC.
How much does DiaMedica Therapeutics spend on research and development?
$24.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does DiaMedica Therapeutics have?
$43.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest DiaMedica Therapeutics (DMAC) stock news?
Our latest story on DiaMedica Therapeutics, dated Aug 12, 2025: "DiaMedica Therapeutics sets up $100.0 million at-the-market share program with TD Cowen". DiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance. Source.
How long will DiaMedica Therapeutics's cash last?
From our story of Aug 12, 2025: Neither the registration statement nor the 8-K gives a cash balance, a net loss or a cash runway, so the $100.0 million program cannot be set against the company's cash needs. Source.
Investor discussion: DiaMedica Therapeutics
Members talk about DiaMedica Therapeutics (DMAC). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at DiaMedica Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:DMAC on TradingView.
SEC filings and registration
SEC name
DiaMedica Therapeutics Inc.
CIK
1401040
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
DMAC (Nasdaq)
State or country of incorporation
Z4
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305
Phone
(763) 496-5454
Shares outstanding
53,925,697 as of 2026-08-03 (10-Q filed 2026-08-10)
Former names
DiaMedica Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
DiaMedica Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DMAC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio